Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inge M W Verberk

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Epilepsia|March 30, 2026
Serum NfL, GFAP, and p-tau217 in adults with drug-resistant epilepsy and intellectual disabilities: Signs of ongoing neural injuryHadassa Kwetsie, Inge M W Verberk, Jans S van Ool, et al.
Alzheimer'S Research & Therapy|December 6, 2020
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosisSteffi De Meyer, Jolien M Schaeverbeke, Inge M W Verberk, et al.
Alzheimer'S Research & Therapy|February 6, 2026
Real-world diagnostic performance of blood-based biomarkers for Alzheimer's disease: robust performance except after stroke and high charlson comorbidity indexSinthujah Vigneswaran, Inge M W Verberk, Rebecca Z Rousset, et al.
JAMA Network Open|July 10, 2025
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical SpectrumDiederick M de Leeuw, Calvin Trieu, Ellen M Vromen, et al.
Frontiers in Psychiatry|June 25, 2025
Longitudinal associations between amyloid and symptoms of depression and anxiety in subjective cognitive decline: the impact of personality characteristicsCalvin Trieu, Mardou S S A van Leeuwenstijn, Lisa-Marie Schlüter, et al.
Neurobiology of Aging|February 22, 2020
Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe projectInge M W Verberk, Heleen M A Hendriksen, Argonde C van Harten, et al.
International Journal of Molecular Sciences|November 17, 2020
CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's DiseaseLinda P Oosterveld, Tessa I Kuiper, Nour K Majbour, et al.
Brain Communications|February 24, 2023
Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 yearsAnouk den Braber, Inge M W Verberk, Jori Tomassen, et al.
Journal of Alzheimer'S Disease : JAD|March 15, 2024
Alzheimer's Disease and Cognitive Decline in Patients with Cardiovascular Diseases Along the Heart-Brain AxisCalvin Trieu, Argonde C van Harten, Anna E Leeuwis, et al.
Neurology|February 3, 2022
Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive DeclineJarith L Ebenau, Wiesje Pelkmans, Inge M W Verberk, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Epilepsia|March 30, 2026
Serum NfL, GFAP, and p-tau217 in adults with drug-resistant epilepsy and intellectual disabilities: Signs of ongoing neural injuryHadassa Kwetsie, Inge M W Verberk, Jans S van Ool, et al.
Alzheimer'S Research & Therapy|December 6, 2020
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosisSteffi De Meyer, Jolien M Schaeverbeke, Inge M W Verberk, et al.
Alzheimer'S Research & Therapy|February 6, 2026
Real-world diagnostic performance of blood-based biomarkers for Alzheimer's disease: robust performance except after stroke and high charlson comorbidity indexSinthujah Vigneswaran, Inge M W Verberk, Rebecca Z Rousset, et al.
JAMA Network Open|July 10, 2025
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical SpectrumDiederick M de Leeuw, Calvin Trieu, Ellen M Vromen, et al.
Frontiers in Psychiatry|June 25, 2025
Longitudinal associations between amyloid and symptoms of depression and anxiety in subjective cognitive decline: the impact of personality characteristicsCalvin Trieu, Mardou S S A van Leeuwenstijn, Lisa-Marie Schlüter, et al.
Neurobiology of Aging|February 22, 2020
Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe projectInge M W Verberk, Heleen M A Hendriksen, Argonde C van Harten, et al.
International Journal of Molecular Sciences|November 17, 2020
CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's DiseaseLinda P Oosterveld, Tessa I Kuiper, Nour K Majbour, et al.
Brain Communications|February 24, 2023
Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 yearsAnouk den Braber, Inge M W Verberk, Jori Tomassen, et al.
Journal of Alzheimer'S Disease : JAD|March 15, 2024
Alzheimer's Disease and Cognitive Decline in Patients with Cardiovascular Diseases Along the Heart-Brain AxisCalvin Trieu, Argonde C van Harten, Anna E Leeuwis, et al.
Neurology|February 3, 2022
Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive DeclineJarith L Ebenau, Wiesje Pelkmans, Inge M W Verberk, et al.
Pageof 8